Banerjee Ronadip R, Lazar Mitchell A
Division of Endocrinology, Diabetes, and Metabolism, Penn Diabetes Center, University of Pennsylvania School of Medicine, 415 Curie Blvd., Philadelphia, PA 19104-6149, USA.
J Mol Med (Berl). 2003 Apr;81(4):218-26. doi: 10.1007/s00109-003-0428-9. Epub 2003 Mar 28.
Obesity and diabetes have reached epidemic proportions worldwide. The antidiabetic thiazolidinedione (TZD) drugs are insulin-sensitizing agents now widely used in the treatment of type 2 diabetes. TZDs are ligands for the nuclear hormone receptor peroxisome proliferator activated receptor gamma, which is a master regulator of adipogenesis and adipocyte metabolism. The molecular mechanisms by which TZDs improve insulin sensitivity have not been fully identified. Here we consider a novel secreted factor first identified as a TZD-suppressible gene in mouse adipocytes, called resistin, and discuss what is currently known about resistin regulation and function in mouse and human.
肥胖和糖尿病在全球范围内已达到流行程度。抗糖尿病噻唑烷二酮（TZD）药物是目前广泛用于治疗2型糖尿病的胰岛素增敏剂。TZD是核激素受体过氧化物酶体增殖物激活受体γ的配体，该受体是脂肪生成和脂肪细胞代谢的主要调节因子。TZD改善胰岛素敏感性的分子机制尚未完全明确。在这里，我们考虑一种首次在小鼠脂肪细胞中被鉴定为TZD可抑制基因的新型分泌因子——抵抗素，并讨论目前已知的关于抵抗素在小鼠和人类中的调节及功能。
